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Executive Summary  
  
The main point of this analysis was to investigate the diffusion of the cholera vaccination through 
specific layers of the skin. The antigen was initially modeled through the skin directly to the blood stream. The 
antigen was also modeled with the presence of a network of Langerhans cells. There was a smooth concentration 
profile in the skin after one week of patch exposure in the absence of the LC network. However, there was 
discontinuity in the concentration profile when the LC network was present. The LC network functioned as a 
large enough sink term that the flux into the bloodstream was virtually zero. Therefore, we concluded that the 
LC network alone can create a cutaneous immune response. The LC network was enhanced with the presence of 
Imiquimod, a typical immune response modifier. The modifier increased the activity of the LC network, thus 
increasing the reaction rate of the LC cells. With Imiquimod there was a sharper discontinuity in the 
concentration profile at the LC network and the antigen flux into the blood stream is zero.   
The most effective enhancer tested was the MEMs microneedles, which increased the porosity of the 
skin and thus the diffusivity of the antigen through the skin. Contour plots of the skin showed absolute diffusion 
and consumption of the antigen into the LC network, while only partial consumption with the other enhancers 
tested. Concentration gradients were present in the ultrasonically and photo mechanically enhanced skin because 
they had weaker enhancing capabilities compared to the MEMs needles. The MEMs needles are the most 
effective in mass transfer, but are also the most evasive.  
Vaccines are usually given in cycles to increase the concentration of the antigen in the skin and 
bloodstream. When the patch was applied to the skin with no enhancer, the maximum concentration was 
achieved after 2.3 days. However, the maximum concentration in the skin is achieved sooner with the various 
adjuvants. For example, when the patch is applied with MEMs needles, the maximal concentration is achieved 
in the skin only after 1.2 hours of exposure. Immunization cycles presented in Glenn et al were simulated to 
determine the approximate concentration of the antigen at the center of the skin needed for an immune response. 
This concentration is 0.0038 mol/m^3. Therefore, it was assumed that if the concentration in the skin is close to 
this value, then an immune response will be initiated. The immunization cycles for each adjuvant used were then 
optimized.  
 
 
 
 
 
 
 
 
 
 
 
 Introduction and Design Objective  
 
This project is aimed towards analyzing and optimizing an effective method for human transcutaneous 
immunization against the cholera toxin.  The causative agent of cholera, Vibrio cholerae, generates acute 
diarrhea in infected individuals in which, without proper treatment, death is inevitable. A relatively ancient 
disease, the first acute cases were documented in Calcutta, India in the early 1800’s. Since then, over seven 
epidemics have occurred in densely populated areas of South America, Great Britain, China and sub-Saharan 
Africa. Over the last century, Cholera occurrences in the Western world are rare, but it continues to plague Third 
world countries, especially in South Asia.  Today, over eight million patients suffer from Cholera in just South 
India alone. With high mortality rates, augmented by unsanitary water, it is essential to improve vaccines and 
delivery. 
Vibrio cholerae infects humans by consumption of raw meats, drinking of infected water, or 
contamination from fecal matter. The curved-rod shaped bacteria, once inside the host, colonize the lumen of the 
small intestine. There, the secreted Cholera toxin initiates a cascade that produces a rapid flux of bodily fluids 
into the small intestine, resulting in massive diarrhea. Due to the loss of fluids, patients exhibit dehydration, 
vomiting and muscle cramps. Intravenous solutions are used to hydrate patients and intense antibiotic therapy is 
immediately commenced. 
The Cholera toxin, shown in Figure 1, belongs to a family of structurally similar bacterial enterotoxins. 
These toxins are hexameric and consist of AB
5  subunit structures. The A subunit usually has enzymatic 
properties that play an essential role in the disease pathway. The pentameric B subunits usually play a targeting 
role. Toxins that are included in this family include: shiga toxin, pertusis toxin, and diphtheria toxin. Also, the 
heat-labile E. coli toxin has AB
5 morphology and has 80% sequence homology to the Cholera toxin. (Zhang et al., 
1995)  
 
Figure 1: Side view of the cholera toxin. The red subunit, designated as the A1, has a catalytic domain, 
which is connected to the yellow A2 α-helix. A1 and A2 are produced from one polypeptide chain, but 
they are cleaved during toxin processing. The A2 polypeptide penetrates the core of the blue pentameric B 
subunit. 
 
Transcutaneous immunization involves the application of a thin patch to skin to expose a patient to an 
antibody proliferating antigen. Studies conducted by Glenn et al reveal that a mixture of the dissociated subunits 
of the cholera toxin when administered as a vaccine produces a strong immune response in mice. In this study 
we will use the beta subunit as our antigen. The presence of the beta subunit in the skin will cause an immune 
response and the production of antibodies. For details on a transcutaneous immune response, refer to Figure 2 in 
the appendix. Situation I-Antigen Modeled to the Blood Stream     
The patch will be placed on the epidermis of the skin and the antigen will diffuse through the dermis and 
into the bloodstream. As depicted in figure 3, we modeled the patch as a circle, so that we are able to simplify 
the model using axisymmetric properties. The circular path dimensions will have the same area as the square 
path used by Glenn et al. in their study. We will include an additional area of skin around the patch in our 
analysis to understand the effects of lateral diffusive mass transfer, as shown in Figure 4. We will assume that 
the skin acts as a porous material and we will use Fick’s law of diffusion to model mass transfer.       
   0.0282m   
 
 
 
 
 
 
 
 
Figure 3: The patch size designated in Glenn et al. is a square patch with 0.05m side. The area of the square path was converted to a 
circular patch with radius of 0.0282m and thickness of 0.000625m.   
 
Figure 4:  Schematic of simulation with a patch containing an initial concentration of the vaccination, the skin, and the blood stream. 
Boundary conditions and layer dimensions are specified.  
 
 
We made numerous assumptions in modeling the diffusion of the antigen to the blood stream. We 
assumed that the diffusivity coefficients were constant within each layer. The epidermis is the rate-limiting layer 
in the skin. There is no metabolic/consumption reaction within the patch and skin. Skin dermis and epidermis 
dimensions are average values. The patch occupies very small area of overall skin surface. The system is 
isothermal. Blood flow at the skin-dermis interface immediately removes the antigen. The diffusion coefficient 
in the drug reservoir is equal to the diffusion coefficient in adhesive layer. 
 
 
 
  0.000625m   Situation II-Antigen Modeled to the Langerhans Cell Network 
Studies by Suzuki et al reveals that the antigen does not need to reach the blood stream for an immune 
response. Active immunity can occur at the cutaneous level. The dermis is replete with immune cells called 
Langerhans Cells (LCs) which are in close proximity to the most powerful superficial layer of the skin called the 
stratum corneum.  These cells are derived from a macrophage-monocyte precursor in the bone marrow.  This 
allows us to model the LCs with macrophage cellular kinetics (including the rate of antigen uptake and the 
reaction kinetics that follow).  These Langerhans Cells form a monolayer network of immune cells that are 
evenly distributed throughout the suprabasal layer of the epidermis.  The network underlies 25% of the skin’s 
total surface area and has no direct physical contact between dendritic processes. When LCs carry antigen to the 
draining lymph nodes, a systemic immune response is induced.  To achieve immunity, the cholera antigens must 
migrate and bind to regularly ordered networks of langerhans cells of density of 800 cells/mm
2. The Langerhans 
cells carry antigens to the draining lymph nodes where systemic immune responses are induced. Therefore, as 
long as the concentration of antigen is enough in the superficial layers of the skin, active immunization will 
occur. Figure 5 is a schematic of situation two, where the langerhans cell network is depicted by the yellow 
mesh layer. 
 
Figure 5:  Schematic of situation 2 where the patch is placed on the skin and the antigen diffuses through the first layer of skin to the 
Langerhans Skin Network, then passes through the rest of the skin into the blood stream. 
 
 
 
 
 
 
 
  
 
 Situation III-Antigen Modeled to Langerhans Cells with Imiquimod 
 
Immunological adjuvants were originally described as substances that will be used in combination with 
a specific antigen that can produce more immunity that the antigen alone.  In medicine, adjuvants are special 
agents that can modify the effect of other agents while having no direct effects when given by themselves.  An 
adjuvant can be roughly thought of as a chemical catalyst for a reaction.  In immunology, they are often used to 
augment the efficacy of the vaccine by stimulating the immune system to respond to the vaccine with much 
more vitality that it would without the adjuvant.  The presence of adjuvant followed by vaccination will greatly 
increase the innate immune responses to the antigen by augmenting the activities of such biological components 
as the dendritic cells, lymphoctyes, and macrophages.  Imiquimod as a adjuvant has shown to enhance the 
cuteneous immune response while having anti-viral and anti-tumor effect.  After treatment of imiquimod, the 
density of the Langerhans Cells decreased by 43%.  This decreased number of langerhans cells in the skin is the 
direct result of enhanced migration of the cells from the skin to the lymph nodes.  Even though the density of the 
LC network has been so drastically reduced, the immunization level will remain the same or will increase since 
the LC sensitivity is greater.   
 
Figure 6:  Schematic of situation 3 where a patch is placed on skin.  The antigen diffuses through the first skin layer into the Langerhans 
Cell Network.  Here, it is picked up by highly active cells while passing epithelial cells that have taken the place of the moving 
langerhans cells.  The antigen then passes through the rest of the skin into the bloodstream. 
 
 
 
 
 
 
 
 
 
 Situation IV-Antigen Modeled with Physical Disruption of the Patch-Skin Barrier 
 
MEMS-based fabrications allows for the development of micron-scale projections (approximately 
150mm) which can penetrate the outermost layers of the skin. Devices containing microfabricated silicon 
projections called microenhancer array (MEA) have been used to deliver vaccines epidermally.  The device 
mechanically breaches the skin barrier and enables the topical delivery of the vaccine without the need for 
complex or potentially unsafe formulations. In this simulation, the device is used to mechanically disrupt the 
skin, then putting our patch over the mechanically disrupted section of skin. The permeability of the skin is 
being effectively increased by increasing the poreosity of the skin.  
By applying ultrasound at therapeutic frequencies (~1 MHz), growth and oscillation of air pockets 
present in the keratinocytes of the stratum corneum is induced. This proven phenomenon is known as cavitation. 
The oscillations produced will disorganize the stratum corneum lipid bilayers. This disorganization enhances 
transdermal transport.  In order to apply the ultrasound, a transducer is applied to a patch of skin (about 1 cm
2 at 
a time) while oriented perpendicular to the skin. A safe distance of 1 cm from the skin was used to hold the 
transducer.  Human skin permeability to substances such as insulin was found to be much higher after the 
ultrasound was applied.   
When rapid transcutaneous delivery is desired, a mechanical stress pulse generated by a single laser 
pulse is shown to transiently increase the permeability of the stratum corneum in vivo.  After the application, the 
stratum corneum is shown to have fully recovered within minutes.  Within those few minutes, the increase in 
permeability of a section of skin allows macromolecules to diffuse through the epidermis and dermis of the skin.  
Whereas the action of the ultrasound (above) is primarily mediated by heat and cavitation, photomechanical 
wave effects are caused by mechanical forces.   
 
Figure 7:  Schematic (in general) of the 3 different types of the situation in which the skin barrier is penetrated.  The antigen has a higher 
diffusivity through the skin because of this decreased barrier. 
Table 1 below summarizes the input parameters in modeling the four situations and their respective references. Parameter  Value  Reference 
Diffusivity antigen in patch  DP = 1.15 x 10
-10 m
2/s  Antigen modeled through hydro gel. Value taken from 
previous BEE 453 reports. 
Diffusivity antigen in Skin  DD = 6 x 10
-12 m
2/s  Value was taken from BEE 453 reports from previous 
years for the diffusion of large proteins/drugs in skin.  
Diffusivity antigen through LC network  DLC = 3 x 10
-12 m
2/s  Modeled as equivalent situation of drug diffusing through 
neuronal networks in brain. (Robinson et al, 1990)  
Diffusivity of skin after MEMs needles  DMEMs =  6 x 10
-9 m
2/s  Mikszta et al., 2002 
Diffusivity of skin after ultrasonic 
enhancement 
DULTRA =  3 x 10
-11 m
2/s  Mitragotri et al., 1995 
Diffusivity of skin after photomechanical 
enhancement 
DPHO =  1.68 x 10
-11 m
2/s  Lee et al., 1998  
1
st order rate constant, K for LC network  K  = 5.5 x 10
-6 m
2/s   Modeled from first order kinetics of phagocytes. (Leijh et 
al., 1979) 
1
st order rate constant, K for LC network 
with the presence of Imiquimod 
K  = 1.1 x 10
-5  m
2/s   Modeled from data presented in publication. (Suzuki et al., 
2000) 
Initial concentration of antigen in skin  CD, initial = 0 mol/m
3 There is no toxin in the skin before application of the 
patch.  
Initial concentration of antigen in patch  CD,patch= 0,01739 mol/m
3 Modeled as the patch used in Glenn et al. 
 Table 1 summarizes the input parameters. 
 
 
Design Objectives 
  The purpose of this design project is to model the diffusion of the cholera antigen in the human skin to 
improve our understanding of the transcutaneous immunization. We will first characterize the diffusion of the 
antigen from the patch to the blood stream, where the concentration of the antigen is considered zero. We will 
then determine how this process is affected by the inclusion of a Langerhans network, which acts as a sink term 
for the antigen. To further characterize the Langerhans network’s affects on mass transfer, we will incorporate 
the adjuvant, Imiquimod, into our model. Various other adjuvants or enhancers will be incorporated into our 
model to see how changing diffusivity of the skin affects mass transfer with the presence of a Langerhans 
network.  
  After characterizing the different situations presented above, we will shift our focus to analyzing 
immunization cycles for the cholera vaccine. We start by modeling the immunization cycles presented in Glenn 
et al. Patients received 500 µg of cholera antigens in 500µl of saline, adsorbed on a 0.05 x 0.05 m
2 single-ply 
polyester-rayon gauze pad with polyethylene backing covered by a 10 x 12 cm
2 Tegaderm dressing.  The patch 
was placed on the upper arm for 24 hours, after which it was removed and the site was rinsed with 500mL of 
sterile saline.  Individuals were re-immunized after 24 hours. From modeling this situation, it is possible to 
determine the maximum concentration in the skin necessary for an immune response, since Glenn et al observed a four fold increase in antibody concentration in the blood. Then, we will model the same immunization cycles 
for the adjuvants and enhancers. We then optimize the immunization cycles for these various adjuvants. 
Characterize diffusion of 
cholera antigen in skin 
with patch. 
Characterize diffusion with 
Langerhans Network. 
Characterize diffusion with 
Langerhans Network and 
Imiquimod. 
Model immunization cycles 
as presented in Glenn et al. 
Determine maximum skin 
concentration of antigen 
reached in cycles necessary 
for immune response. 
Characterize diffusion with 
adjuvants/enhancers 
MEMS Needles 
Ultrasonic 
Enhancement 
Photomechanical 
Enhancement 
Optimize immunization 
cycles for the 
adjuvants/enhancers and 
compare with Glenn et al. 
 
Figure 8: Overall scheme of project. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Results and Discussion 
 Figure 9 is the mesh we used to model the antigen diffusion through the skin. Higher densities of 
elements were used at the patch-skin interface to accurately model the transfer. We used a structured mesh to 
shorten computation times. Figure 10 is the mesh we used to model the antigen diffusion through the LC 
network and to the blood stream. We used an unstructured mesh to produce detailed contours in the LC network 
and patch-skin interface. 
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Figure 11: Cross sectional concentration profiles with the LC network included or excluded in the modeling analysis.  
 
Figure 11 reveals the concentration profile at the center of the skin after the patch has been applied over 
a period of one week. When we do not include the LC network in our model, the concentration of the antigen 
peeks at about 2.3 days. When we include the LC network, the concentration profile is shifted to left, indicating 
that peak concentrations are achieved in the skin at short time periods. The decrease in peak antigen 
concentration is attributed to the sink nature of the LC network. When Imiquimod is added as an enhancer to the 
skin, the LC network is hyperactive and the sink nature of the network is increased. This is shown with a 
downward shift in the concentration profile shown in figure 11.    
Figure 12 is a contour map of the diffusion of the antigen to the Langerhans Cells with the presence of 
Imiquimod, a typical immune response modifier. The modifier increases the activity of the LC network, thus 
increasing the reaction rate constant. According to figure 12, there is a sharper discontinuity in the concentration 
profile at the LC network and the antigen flux into the blood stream is virtually zero.  We now move to the second part of our results involving the maximization of immunization trials. 
Vaccines are usually given in cycles to increase the concentration of the antigen in the skin and bloodstream. It 
is important to note that by simply placing a patch on a patient for many weeks will only result in a certain 
maximum concentration. This concentration may not be sufficient for an immune response. Figure 13 exhibits 
this result. When the patch is applied to the skin with no enhancer, the maximum concentration is achieved after 
2.3 days. However, the maximum concentrations in the skin are achieved sooner with the various adjuvants. For 
example, when the patch is applied with MEMs needles, the maximal concentration is achieved in the skin only 
after 1.2 hours of exposure. 
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Figure 13:  Concentration profile at center of skin region over 1 week of exposure the Cholera vaccine patch.  
 
  Figure 14 shows the concentration profile of the antigen at the center of the skin region during the 
immunization cycle outlined in Glenn et al. The researchers devised an immunization cycle to increase the 
concentration of the antigen in skin and bloodstream, enough so that a potent immune response was initiated. 
We simulated these cycles to determine the approximate concentration of the antigen at the center of the skin 
needed for an immune response. According to Figure 14, this concentration is 0.0038 mol/m^3. We therefore, 
assume that if the concentration in the skin is close to this value, then an immune response will be initiated. 
However, according to the Figure 14, if we use the same immunization cycles with the presence of the 
adjuvants, the maximum concentration reached is always below 0.0038 mol/m^3. We then optimized the 
immunization cycle for each adjuvant used to increase the maximal concentration. Concentration Profile at Center of Skin During Immunization Cycle
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Figure 14:  Concentration profile at the center of the skin region after exposure to immunization cycles outlined in Glenn et 
al. Patch was placed on patients arm for 24 hours, after which is was removed for 24 hours. A fresh patch was then applied 
again for 24 hours.    
 
Concentration Profiles at Center of Skin with Altered Immunization Cycles
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Figure 15:  Concentration gradient of antigen over 1 week when the diffusivity is 1.68*10^(-11) after photomechanical 
forces have been applied to the skin. 
   We ran multiple trials with varying times for path exposure and patch removal times. We used the date 
presented in figure 15 to determine when the concentration peaks in each case. We determined that if we apply 
the patch to the skin just long enough until the concentration peaks and then remove the path and apply a fresh 
patch after a period of time, we can achieve a high concentration. Figure 15 is the result of several trials and 
represents the best immunization trials in the presence of the adjuvants.   
 
Sensitivity Analysis 
 
  We conducted a sensitivity analysis to determine the affect on the rate constant, k, for the consumption 
of the antigen by the LC network (figure 16). This value was provided to use from publications based on first 
order enzymes kinetics. However, there was a range of values given, which indicates uncertainty with this value. 
 
Sensitivity of k
0.00E+00
1.00E-04
2.00E-04
3.00E-04
4.00E-04
5.00E-04
6.00E-04
7.00E-04
8.00E-04
9.00E-04
0.55
0.055
0.0055
0.00055
0.000055
0.0000055
5.5E-07
5.5E-08
5.50E-09
5.50E-10
5.50E-11
k 
A
v
e
r
a
g
e
 
C
o
n
c
 
(
m
o
l
/
m
^
3
)
Series1
 
 
Figure 16: Sensitivity analysis results of k constant.  
 
 We also conducted a sensitivity analysis to determine the affect of the diffusivity of the antigen through 
the skin (figure 17). This value was based on previous case studies in BEE 453.  
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Figure 17: Sensitivity analysis results of  diffusivity coefficient..  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Conclusions and Design Recommendation  
 
The main point of this analysis was to investigate the diffusion of the cholera vaccination through 
specific layers of the skin. This simulation consisted of a 2-D model of a piece of human skin and bloodstreams 
that imitates drug delivery via a patch that is placed onto the skin. It is assumed that all skin layers have the 
same diffusive properties. Since the patch will release the antigen in an intravenous fashion equivalent to doses 
injected manually, our method is advantageous over repeated doctor’s visits to get the same treatment.  
The antigen was initially modeled through the skin directly to the blood stream. The antigen was also 
modeled with the present of antigen presenting network of Langerhans cells. There was a smooth concentration 
profile in the skin after one week of patch exposure, but there was discontinuity when the LC network was 
present. The LC network functioned as a large enough sink term that the flux into the bloodstream was virtually 
zero. Therefore, we can say that the LC network can alone create a cutaneous immune response. The LC 
network was enhanced with the presence of Imiquimod, a typical immune response modifier. The modifier 
increased the activity of the LC network, thus increasing the reaction rate of the LC cells. With Imiquimod there 
was a sharper discontinuity in the concentration profile at the LC network and the antigen flux into the blood 
stream is zero.   
The most effective enhancer tested was the MEMs microneedles, which increased the porosity of the 
skin and thus the diffusivity of the antigen through the skin. Contour plots of the skin shows absolute diffusion 
and consumption of the antigen into the LC network, while only partial consumption with the other enhancers. 
Concentration gradients were present in the ultrasonically and photo mechanically enhanced skin because they  
have weaker enhancer capabilities, compared to the MEMs  needles. The MEMs needles are more effective, but 
more evasive.  
Vaccines are usually given in cycles to increase the concentration of the antigen in the skin and 
bloodstream. When the patch was applied to the skin with no enhancer, the maximum concentration is achieved 
after 2.3 days. However, the maximum concentration in the skin is achieved sooner with the various adjuvants. 
For example, when the patch is applied with MEMs needles, the maximal concentration is achieved in the skin 
only after 1.2 hours of exposure. We simulated immunization cycles to determine the approximate concentration 
of the antigen at the center of the skin needed for an immune response. This concentration is 0.0038 mol/m^3. 
We therefore, assume that if the concentration in the skin is close to this value, then an immune response will be 
initiated. We then optimized the immunization cycle for each adjuvant used to increase the maximal 
concentration. Below are the recommended immunization cycles: 
o  MEMS: Place patch on for 1.5 hours, then instantly place another patch for 1.5 hours. 
o  Ultrasonically enhanced skin: Place path on for 18.5 hours, then wait 30 minutes before 
applying another patch for 18.5 hours. o  Photo mechanically enhanced skin: Place patch on for 1.1 days, then wait 5.5 hours before 
applying another patch for 1.1 days. 
When designing a biomedical product, it is important to consider realistic constraints that may affect 
implementation of the product.  One such concern in our design would be the health and safety of the patient 
using the patch.  Typically with such patches, common side effects include things like nausea, blood clot, and 
fatigue. We would need to conduct further testing to ensure that the patch is safe for use and that these and other 
potential side effects are minimal and have little or no chance of escalating into a more serious problem.  It is 
also crucial to test the effects of using the patch while being on other medication or while having other medical 
conditions.  A related ethical concern would be in regards to experimentation on humans and animals.   
Furthermore, since the patch is designed for home use it should be made safe for disposal and manufactured 
from materials that meet environmental standards.  In third world regions such as Africa and India, the patch 
would be safer than the traditional vaccination via needles.  There is usually lack of hygiene in some of these 
underdeveloped areas, and improper use of needles can lead to transmission of other diseases like AIDS. Since 
the patch is meant for single use and does not come into contact with disease-transmitting fluids, it is a much 
safer way to become immunized.  
  Economically speaking, the cholera patch seems to be more cost effective than alternate methods of 
immunization.  One such method is the oral vaccine called Dukoral. It is not available in the United States, but 
is available in other locations abroad.  For the minimum two doses that travelers would be required to take, the 
cost would be about $110.  Although we do not know what the exact cost of our patch would be, we estimate 
around $35 to $45, which is just slightly higher than a month’s supply of the birth control patch.  Another 
restriction with Dukoral is that food consumption cannot occur for one hour before and after consumption, 
whereas with the patch there are no such restrictions. The Dukoral doses also occur over a few months, so it is 
more likely that one would forget when they’re supposed to take the medicine.  The patch is worn short term, so 
it is easy to remember when to take it on and off.  Dukoral also does not provide full immunity until one week 
after dosage begins, however the patch would provide immunity less than a week after it is put on.  Once the 
patch becomes widespread, some cost could potentially be covered under health insurance plans.  In addition, 
the patch is intended for home use which means the cost of medical personnel needed decreases since physicians 
do not need to administer doses. Socially speaking, people are more likely to be comfortable becoming 
immunized because there is a degree of fear associated with injection by needles, as opposed to the patch which 
is extremely user-friendly.       
 
 
 
 
 Appendix A 
 
Governing Equations and Boundary Conditions 
 
Situation 1 
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x = distance 
DD = Diffusivity = 6 x 10
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Initial Conditions 
CD = (t = 0) = 0 in skin 
Boundary Conditions 
CDAt, x = 0.002535m = 0 
Assuming that the bloodstream carries away all of the antigen 
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Initial Conditions 
CD = concentration of antigen 
t = time  
x = distance 
DD = Diffusivity = 6 x 10
-12 m
2/s 
K = .55X10^-5 
 
[8.3] – Situation 3 
Governing Equation 
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CD = concentration of antigen 
t = time  
x = distance 
DD = Diffusivity = 6 x 10
-12 m
2/s Initial Conditions 
CD (t = 0) = 0 in skin 
Boundary Conditions 
1.047 x 10
-11 mol/m
2s  initial flux at patch-skin boundary 
 
Situation 4 
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CD = concentration of antigen 
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t = time  
x = distance 
DD = Diffusivity = varied depending on enhancer used 
Initial Conditions 
CD = (t = 0) = 0 in skin 
Boundary Conditions 
CDAt, x = 0.002535m = 0 
Assuming that the bloodstream carries away all of the antigen 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Appendix B 
 
 
Figure 9:  Mesh applied to Situation 1, a patch on top of the skin layer with antigen diffusing through the skin to the blood stream. 
 
Figure 10:  Mesh of situation 2, a patch on top of the skin layer with antigen diffusing through the LC network and to the blood stream. 
 
and immunizes the human. 
   
 
 
Figure 12:  Concentration gradient of the antigen developed over one week during situation 3. 
 
Below is a mesh convergence analysis (figure 18). We used convergence in relation to average 
concentration because this would give us a very accurate number of elements to use in our analysis. 
We used 77 or greater nodes in our analysis. 
 
Figure 18: Sensitivity of number of nodes to average concentration in the skin.  
Appendix C 
 
 
 
Figure 2: Primary immune response cascade. http://www.transferfactorinstitute.com/ImmuneSystem/basics.cfm  
 
The figure above depicts a primary immune response cascade that will occur after the patient has been 
exposed to cholera toxin antigen through the patch. (1) The antigen will diffuse through the skin layers, 
signaling an immune response from macrophages and other scavenger immune cells. (2) Mast cells release 
chemicals that trigger inflammation, allowing other immune cells to rush to the diffusing antigen. (3) Before 
reinforcements arrive, macrophages and other immune cells start engulfing the antigens. (4) The antigens are 
transported to the lymph nodes where these macrophages bind to B and T cells. B cells begin producing 
antibodies specifically for the particular cholera toxin antigen. (5) The antibodies tripper responses from certain 
immune cells like NK cells, macrophages and killer T cells to engulf and kill the antigen-infected cells. (6 & 7) 
Multiple other steps occur to ensure that there is an immune response to the antigen.  
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